INVEGA 3 MG Israel - English - Ministry of Health

invega 3 mg

j-c health care ltd - paliperidone - tablets extended release - paliperidone 3 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.

INVEGA 6 MG Israel - English - Ministry of Health

invega 6 mg

j-c health care ltd - paliperidone - tablets extended release - paliperidone 6 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.

INVEGA 9 MG Israel - English - Ministry of Health

invega 9 mg

j-c health care ltd - paliperidone - tablets extended release - paliperidone 9 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.

XEPLION 50 MG Israel - English - Ministry of Health

xeplion 50 mg

j-c health care ltd - paliperidone as palmitate - suspension for injection extended release - paliperidone as palmitate 100 mg / 1 ml - paliperidone - paliperidone - xeplion is indicated for the acute and maintenance treatment of schizophrenia in adults.xeplion is indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and antidepressants

REMINYL PRC 8 MG Israel - English - Ministry of Health

reminyl prc 8 mg

j-c health care ltd - galantamine as hydrobromide - capsules prolonged release - galantamine as hydrobromide 8 mg - galantamine - galantamine - reminyl is indicated for the smptomatic treatment of mild to moderately severe dementia of the alzheimer type.

REMINYL PRC 24 MG Israel - English - Ministry of Health

reminyl prc 24 mg

j-c health care ltd - galantamine as hydrobromide - capsules prolonged release - galantamine as hydrobromide 24 mg - galantamine - galantamine - reminyl is indicated for the smptomatic treatment of mild to moderately severe dementia of the alzheimer type.

STUNARONE TABLETS Israel - English - Ministry of Health

stunarone tablets

j-c health care ltd - cinnarizine - tablets - cinnarizine 25 mg - cinnarizine - cinnarizine - symptomatic treatment of nausea and vertigo due to meniere's disease and other labyrinthine disturbances and for travel sickness.

VERMOX SUSPENSION Israel - English - Ministry of Health

vermox suspension

j-c health care ltd - mebendazole - suspension - mebendazole 20 mg/ml - mebendazole - mebendazole - treatment of single or mixed infections of trichuris trichura (whipworm), ascaris lumbricoides (large roundworm), ancylostoma duodenale, necator americanus (hookworm), strongyloides stercoralis, enterobius vermicularis (threadworm/pinworm) and taenia spp.

VERMOX TABLETS Israel - English - Ministry of Health

vermox tablets

j-c health care ltd - mebendazole - tablets - mebendazole 100 mg - mebendazole - mebendazole - treatment of trichuris trichiura (whipworm). ascaris lumbricoides (roundworm). ancylostoma duodenale (common hookworm). necator americanus (american hookworm), strongyloidiasis, enterobius vermicularis (pinworm) and teniasis in single or mixed infections.

PANCREAZE- pancrelipase capsule, delayed release United States - English - NLM (National Library of Medicine)

pancreaze- pancrelipase capsule, delayed release

janssen pharmaceuticals, inc. - pancrelipase lipase (unii: 8myc33932o) (pancrelipase lipase - unii:8myc33932o), pancrelipase amylase (unii: yoj58o116e) (pancrelipase amylase - unii:yoj58o116e), pancrelipase protease (unii: 3560d81v50) (pancrelipase protease - unii:3560d81v50) - pancrelipase lipase 4200 [usp'u] - pancreaze (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. none. teratogenic effects pregnancy category c: animal reproduction studies have not been conducted with pancrelipase. it is not known whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. pancreaze should be given to a pregnant woman only if clearly needed. the risk and benefit of pancrelipase should be considered in the context of the need to provide adequate nutritional support to a pregnant woman with exocrine pancreatic insufficiency. adequate caloric intake during pregnancy is important for normal maternal weight gain and fetal growth. reduced maternal weight gain and malnutrition can be associated with adverse pregnancy outcomes. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when pancreaze is administered to a nursing